cropped-LOGO-PROCURE-SOLUTIONS-DEF.png

ProCure Solutions

Pharmaceutical patient access strategic consultancy
What we do

The need to undertake early market access activities it is linked to the specificity of the Italian context, with specific characterizations at the territorial level with respect to the drug access procedure and with a continuous evolution of the regulation of pharmaceutical expenditure through health policies aimed at improve the management of pharmaceutical expenditure both nationally and locally.


The availability of target therapies targeting subpopulations increasingly selected and rare diseases, along with the more recent introduction of gene therapies and other advanced therapies makes theoptimization of the drug access process increasingly crucial so that this happens in the shortest possible time to guarantee the patient the best treatment opportunities.


ProCure Solutions is a scientific consulting firm that has been operating for over 15 years in the pharmaceutical sector with consolidated experience in health economics activities, market access, pricing, reimbursement of drugs and training.


We support companies at all stages of drug access, of writing manuscripts, of local real world data analysis also thanks to the external support of a multidisciplinary team of highly experienced professionals with regard to clinical evaluations, the development of innovation request documents (including GRADE rating) and the strategic pricing and patient access assessments.

Main areas of activity

Rare diseases

Oncology

Cardiovascular

Rheumatology

Kidney failure

Gastrointestinal disorders

Diseases of the central nervous system

Autoimmune diseases

Infectious diseases

Dermatology

pain

Respiratory pathologies

Transplants

Our services

Who we are

Daniela Paola Roggeri

Founder

Alessandro Roggeri

Market Access & Health Economist
cropped-LOGO-PROCURE-SOLUTIONS-DEF.png

Latest news

European Medicines Agency

  1. Summary of opinion: Hukyndra,adalimumab, 16/09/2021, Positive
    Source: New medicines and SMOPs: human Published on 2021-09-17
  2. Summary of opinion: Firmagon,degarelix, 16/09/2021, Positive
    Source: New medicines and SMOPs: human Published on 2021-09-17
  3. Summary of opinion: Qinlock,ripretinib, 16/09/2021, Positive
    Source: New medicines and SMOPs: human Published on 2021-09-17
  4. Summary of opinion: Brukinsa,zanubrutinib, 16/09/2021, Positive
    Source: New medicines and SMOPs: human Published on 2021-09-17
  5. Summary of opinion: Paliperidone Janssen-Cilag International,paliperidone, 17/09/2021, Positive
    Source: New medicines and SMOPs: human Published on 2021-09-17